INBX Stock Analysis: Buy, Sell, or Hold?
INBX - Inhibrx Biosciences, Inc. Common Stock
$103.63
4.48 (4.52%)
▲
5d:
+17.27%
30d:
+21.92%
90d:
-6.28%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When INBX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: INBX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: INBX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: INBX is currently trading at $103.63, which is considered extended relative to its 30-day fair value range of $82.18 to $95.30.
Technical Outlook: Technically, INBX is showing sideways momentum. The price is approaching resistance at $105.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: INBX scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $277.50 (+167.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INBX is showing sideways momentum. The price is approaching resistance at $105.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: INBX scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $277.50 (+167.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$82.18 -
$95.30
Company Quality Score
39/100
(SELL)
Options IV Signal
30th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
35.4%
Protect Your Profits
Holding INBX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+8.7% above its trading range)
- NEUTRAL: Options fairly priced (IV 30th percentile)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.5%)
- BULLISH: Trading 167.8% below Wall St target ($277.50)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$82.18 -
$95.30
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$15.21
(14.7%)
Support & Resistance Levels
Support Level
$85.06
Resistance Level
$105.65
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.45
Wall Street Target
$277.50
(+167.8%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 23, 2026 1:57 AM ET
Data refreshes hourly during market hours. Next update: 2:57 AM
Data refreshes hourly during market hours. Next update: 2:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INBX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
Advanced INBX Option Strategies
Professional options setups generated by AI based on today's INBX price and gamma walls.
